Navigation Links
Antibody-guided drug works against acute lymphoblastic leukemia
Date:5/23/2011

HOUSTON An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

Patients enrolled in the trial led by investigators at The University of Texas MD Anderson Cancer Center had ALL that resisted other therapies or recurred after treatment.

"A response rate of more than 50 percent in this patient population probably makes inotuzumab ozogamicin the most active single-agent therapy ever for ALL," said Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia and study senior investigator.

ALL is an aggressive form of leukemia in which immature white blood cells, called lymphoblasts, grow rapidly, crowding out normal blood cells.

The drug, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells, and the cytotoxic agent calicheamicin. Once the drug connects to CD22, the ALL cell draws it inside and dies.

Response rate for other second options is 20-30 percent

Kantarjian said second-line chemotherapy combinations used for ALL typically have a complete response rate of 20-30 percent. The monoclonal antibody-based drug developed by Pfizer, Inc., also is the first of its type for ALL.

The drug is safe, said Elias Jabbour, M.D., assistant professor in MD Anderson's Department of Leukemia, who will present the study results at ASCO on Monday, June 6. Almost all side-effects were of low grade (1-2) and manageable. Drug-induced fever was the most common side effect, reaching higher grades in nine of 48 patients.

Out of 46 patients evaluable for response, nine had a complete response, 14 had complete response without full recovery of platelets, and 5 had less than 5 percent blasts in their bone marrow without blood count recovery.

Sixteen responders subsequently received a donor blood stem cell transplant, Jabbour noted.

Drug combinations

Combining inotuzumab with other chemotherapy might further improve ALL treatment, Jabbour said. MD Anderson has a phase II clinical trial under way following inotuzumab treatment with another monoclonal antibody drug, rituximab, currently used in some types of non-Hodgkin's lymphoma.

Rituximab targets the CD20 surface protein, which occurs in 50 percent of ALL cells.

In addition to combinations, the authors suggest that a shift from dosing every three weeks to weekly should be explored.

Frontline therapy for ALL is a combination chemotherapy regimen known as HyperCVAD.

The National Cancer Institute estimates that 5,330 people received an ALL diagnosis in 2010 and 1,420 died of the disease.

ALL is the most common type of childhood cancer. Combined chemotherapy regimens have raised long-term survival from 5 percent of pediatric patients in the 1960s to 85 percent today.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. KPA and TK Carsites offer HR, OSHA and Internet Marketing Workshops at the NADA Convention and Expo 2010
2. For Some Breast Cancer Patients, Shorter Radiation Works Well
3. Swine Flu vaccination: voluntary system works
4. mHealth Alliance Works in Partnership with GSMA to Expand Discussion of Mobile Health at 2010 Mobile World Congress
5. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
6. Visionworks(R) Brings High Quality Eye Care & Eye Wear to Western PA
7. Dr. Alesia Wagner of U.S. HealthWorks Medical Group Re-elected to Board of Osteopathic Physicians and Surgeons of California
8. Abbott Research Group, Inc. Launches New Product - WaterWorks
9. Learn to Dance in a Day -- Beginner Workshop Launches Modern Jive in Toronto
10. Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState
11. Easy to See and Use Senior Phone Works with AT&T and T-Mobile Cellular Providers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibody-guided drug works against acute lymphoblastic leukemia
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: